Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Pushes For Compulsory Licensing Of Drugs & Vaccines In Health Crises

Activists Welcome 'Surprise' Move But Industry Disappointed

Executive Summary

The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.

You may also be interested in...



Industry Skeptical Of EU Moves To Facilitate Compulsory Licensing

Industry representatives in the EU are more welcoming of moves to harmonize supplementary protection certificates, which they say will bring more certainty for stakeholders.

EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing

The EU has announced two separate legal initiatives, one that would improve IP protections, and another that could weaken them in the event of a future health crisis.

EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing

The EU has announced two separate legal initiatives, one that would improve IP protections, and another that could weaken them in the event of a future health crisis.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel